niacinamide has been researched along with Triple Negative Breast Neoplasms in 7 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because dosing delays and modifications were associated with the MTD, the recommended phase II dose was declared to be pemetrexed 500 mg/m2 every 14 days with oral sorafenib 400 mg given twice daily on days 1-5." | 2.82 | Phase I study of pemetrexed with sorafenib in advanced solid tumors. ( Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Jung, M | 1 |
| Lee, KM | 1 |
| Im, Y | 1 |
| Seok, SH | 1 |
| Chung, H | 1 |
| Kim, DY | 1 |
| Han, D | 2 |
| Lee, CH | 2 |
| Hwang, EH | 1 |
| Park, SY | 1 |
| Koh, J | 1 |
| Kim, B | 1 |
| Nikas, IP | 1 |
| Lee, H | 2 |
| Hwang, D | 1 |
| Ryu, HS | 2 |
| Maric, T | 1 |
| Bazhin, A | 1 |
| Khodakivskyi, P | 1 |
| Mikhaylov, G | 1 |
| Solodnikova, E | 1 |
| Yevtodiyenko, A | 1 |
| Giordano Attianese, GMP | 1 |
| Coukos, G | 1 |
| Irving, M | 1 |
| Joffraud, M | 1 |
| Cantó, C | 1 |
| Goun, E | 1 |
| Song, W | 1 |
| Hwang, Y | 1 |
| Youngblood, VM | 1 |
| Cook, RS | 1 |
| Balko, JM | 1 |
| Chen, J | 1 |
| Brantley-Sieders, DM | 1 |
| Kim, JY | 1 |
| Woo, J | 1 |
| Yue, W | 1 |
| Kim, K | 1 |
| Choi, S | 1 |
| Jang, JJ | 1 |
| Kim, Y | 1 |
| Park, IA | 1 |
| Killock, D | 1 |
| Poklepovic, A | 1 |
| Gordon, S | 1 |
| Shafer, DA | 1 |
| Roberts, JD | 1 |
| Bose, P | 1 |
| Geyer, CE | 1 |
| McGuire, WP | 1 |
| Tombes, MB | 1 |
| Shrader, E | 1 |
| Strickler, K | 1 |
| Quigley, M | 1 |
| Wan, W | 1 |
| Kmieciak, M | 1 |
| Massey, HD | 1 |
| Booth, L | 1 |
| Moran, RG | 1 |
| Dent, P | 1 |
| Liu, CY | 1 |
| Su, JC | 1 |
| Huang, TT | 1 |
| Chu, PY | 1 |
| Huang, CT | 1 |
| Wang, WL | 1 |
| Lau, KY | 1 |
| Tsai, WC | 1 |
| Yang, HP | 1 |
| Shiau, CW | 1 |
| Tseng, LM | 1 |
| Chen, KF | 1 |
1 trial available for niacinamide and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2016 |
6 other studies available for niacinamide and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent.
Topics: Animals; Apoptosis; Cell Line, Tumor; Drug Repositioning; Humans; Lipid Metabolism; Mice; Niacin; Ni | 2022 |
A bioluminescent-based probe for in vivo non-invasive monitoring of nicotinamide riboside uptake reveals a link between metastasis and NAD
Topics: Animals; Biosensing Techniques; Humans; NAD; Niacinamide; Pyridinium Compounds; Triple Negative Brea | 2023 |
Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Topics: Animals; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhib | 2017 |
Reconstruction of pathway modification induced by nicotinamide using multi-omic network analyses in triple negative breast cancer.
Topics: Computational Biology; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gen | 2017 |
Chemotherapy as a TONIC to invigorate PD-1 inhibition in TNBC.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Humans; Niacinamide; Programmed Cell Death 1 Re | 2019 |
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Docetaxel; Drug Synergism; Fema | 2017 |